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Introduction
Fibromyalgia (FM) is a chronic pain syndrome with a high burden for the individual person and for society. The prevalence has been estimated at between 2.1% in Germany [1] and 6.4% in the USA [2] . Patients with FM show a very high health care utilization. They consult more doctors, undergo more pain-related operations and have more pain-related hospital and rehabilitation stays compared to average medical users [3] . FM is characterized by chronic widespread pain, sleep disturbances, and additional symptoms such as fatigue and depression. Some patients report a decline in memory, cognitive function, and mental alertness [4, 5] . Activities of daily living, working ability [6] , and quality of life are considerably limited [7] .
The etiology of FM remains unclear [8] . Evidence-based guidelines for the diagnosis and care of FM patients such as the German Fibromyalgia Guidelines [9, 10] include many treatment options, but provide only few strong recommendations. These strong recommendations include low-to moderate-intensity aerobic exercise and strength training, relaxation techniques combined with aerobic exercise training, cognitive-behavioral therapy combined with aerobic exercise training, and meditative movement therapies (Qi-Gong, Tai Chi, Yoga). For electromyogram biofeedback (EMG-BFB), the German guidelines gives an 'open recommendation', reflecting the low level of evidence [11] .
The principle of biofeedback is to provide audio or visual feedback of body parameters that a person is usually not aware of. An established application of EMG-BFB is the feedback of muscle tension in order to reduce muscle tension and stress. EMG-BFB has been successfully applied in patients with migraine, chronic tension headache, or chronic whiplash-associated disorder. It is safe and has no side effects [12] [13] [14] .
A recent meta-analysis and systematic review of randomized controlled trials (RCTs) in patients with FM included 4 RCTs with EMG-BFB and found significant pain reduction but no improvement of health-related quality of life for EMG-BFB compared to control groups [15] . However, statistical tests suggested publication bias and the methodological quality of the EMG-BFB trial was judged as poor. No RCT adequately reported randomization or blinding of the assessor. In 3 RCTs, patients received additional relaxation techniques besides muscle relaxation based on the EMG-BFB training. Accordingly, it remained unclear if the benefits in these studies were due to the EMG-BFB. The review concluded that future trials should address the deficiencies.
The objective of this RCT was to evaluate the effectiveness of EMG-BFB in patients with FM. The specific aim was to examine the effectiveness of EMG-BFB in improving the health status, measured by the Fibromyalgia Impact Questionnaire (FIQ) [16] [17] [18] [19] [20] . The intervention group received EMG-BFB in addition to the usual medical care. The control group received usual care alone.
Material and Methods

Trial Design
This was a 1-center randomized, assessor-blinded, controlled, parallelgroup clinical trial. Assessments were performed before intervention (baseline, T0), at the end of intervention (T1), and 3 months after the end of intervention (T2). The study was carried out in compliance with the Helsinki Declaration. It was approved by the ethical committee of the Ludwig Maximilian University Munich, Germany (project number 023/05). It is registered at ClinicalTrials.gov (registration number NCT02186756). Registration of the trial was performed only after the study was completed because at the time the trial started, registration was not routinely performed for non-pharmacological studies. The trial was not changed after trial commencement.
Participants
Consecutive patients from a waiting list for an FM day hospital program at the Department of Physical Medicine and Rehabilitation at the Ludwig Maximilian University Munich, Germany, were invited by telephone to participate in the study. If they showed interest, they were scheduled for a screening visit. Inclusion criteria were a diagnosis of FM according to the American College of Rheumatology (ACR) criteria [21] , female gender, age between 18 and 65 years, cognitive ability, and sufficient German language skills to fill in the health status questionnaires and the signed informed consent. Exclusion criteria included major medical disorders, i.e. cancer, chronic heart failure New York Heart Association (NYHA) IV, or asthma requiring cortisone medication, suffering from psychosis or major affective disorders, substance abuse, comedication with opiates or benzodiazepine, a transmeridian flight in the last weeks, shift work, or gravidity.
Data Collection and Randomization Procedure
Patients who were willing to participate were assessed by a specialist in physical and rehabilitation medicine (PRM) at T0. He took the medical history, conducted a general examination including body height, body weight, blood pressure and heart rate, and an FM-specific examination. Then, he checked the inclusion and exclusion criteria. Eligible patients were asked to sign the informed consent.
A block randomization with random block sizes of 2 or 4 was performed by a person who was involved neither in the intervention nor in the assessments. 40 sealed envelopes were labeled with 1-40 according to the consecutively assigned patient numbers. According to random numbers each envelope included the information on group assignment.
Study Intervention
Patients in the intervention group started the EMG-BFB training within 3 days after inclusion. In total, 14 sessions of EMG-BFB were applied. They started with 3 sessions of therapy in weeks 1-3 for a total of 9 sessions. After the first 3 weeks were finished, the patients had 1 session per week in weeks 4-8 for a total of 14 sessions. We applied a more intense training in the beginning because the patients should quickly learn to apply the muscle relaxation exercises on their own. The training was performed with the Schuhfried Biofeedback apparatus and the software Biofeedback 2000 x-pert, which was provided by Schwa-medico (Ehringshausen, Germany). The training was delivered individually to each patient.
The electrodes of the biofeedback apparatus were placed on both the upper and lower trapezius muscle. The grounded electrode was placed on the medial part of the upper trapezius muscle. The apparatus displayed 1 EMG curve for each side that visualized the muscle tension. First, the EMG activity of the trapezius muscle was measured for 5 min in order to obtain a solid baseline. Then, the instructor taught the patients that an ascending curve corresponds to increasing, and a descending curve, to decreasing muscle tension.
After that, the patients were instructed first to consciously strain the trapezius muscles for 3 min and then to relax these muscles for 10 min. They received visual feedback of the muscle tension during these times. The procedure was repeated once. At the end of the training session, the feeling of muscle tension in relation to the EMG-BFB curves was discussed with the patients. Finally, the patients were encouraged to do a home exercise program, in which they consciously relaxed the muscle analogously to the biofeedback session for about 15 min per day. Additionally, they were asked to apply the relaxation technique in stressful situations.
The EMG-BFB was applied by 2 instructors who had both completed a specific course in EMG-BFB before starting the study. One instructor was a medical student in her 4th and 5th year of medical education. The other instructor was a nurse in a chronic pain unit. Every patient was treated by the same instructor in all treatment sessions.
The patients in both the control and the treatment group received the same usual care as they had before starting the study. Both groups were scheduled for multidisciplinary treatment programs after the end of follow-up of this study.
The intervention group was given the second set of questionnaires at the end of the 14th training session (T1), i.e. 8 weeks after T0. The control group received the second set of questionnaires also 8 weeks after T0. Before undergoing the second clinical examination at T1, all patients were instructed not to mention the group assignment to the blinded examiner.
Both groups were sent follow-up questionnaires at 12 weeks after T1. During follow-up, the treatment was not changed. In particular, the patients did not start multidisciplinary treatment.
Outcomes
Sociodemographic characteristics were assessed in a standardized fashion by questionnaire. Comorbidities were evaluated by the Self-Administered Comorbidity Questionnaire [22] .
The primary outcome was the change of the FIQ scores between T2 and T0. The FIQ is a disease-specific multidimensional self-administered health status questionnaire that covers the dimensions: physical functioning (11 items), wellbeing (1 item), work situation (2 items), pain (1 item), fatigue/sleep (2 items), stiffness (2 items), and psychological symptoms (2 items). Scoring ranges from 0 (best health) to 80 (worst health). The FIQ is recommended as a highly sensitive outcome measure in patients with FM [16] [17] [18] [19] . We applied the validated German version [20] .
Secondary outcome measures included the German version of the ShortForm 36 (SF-36), which measures health-related quality of life [23] [24] [25] . Its 8 scales cover the domains 'Physical Functioning', 'Role-Physical', 'Bodily Pain', 'General Health', 'Vitality', 'Social Functioning', 'Role-Emotional', and 'Mental Health'. Each scale ranges from 0 (worst) to 100 (best). Change of health was directly measured by the self-rated Patient's Global Impression of Change (PGIC), which includes a 6-point rating scale from 'very much worse' (score 1) to 'very much better' [26] . Depression was assessed by the Beck Depression Inventory (BDI). It comprises 21 items that assess cognitive, affective, and neurovegetative factors associated with depression [27, 28] . The score ranges from 0 to 63. Scores above 11 indicate mild to moderate depressive symptoms; scores above 18 indicate clinically relevant depression [29] .
Further, the Symptom Checklist 90 Revised (SCL-90-R) was used for measuring psychological distress. It generates 9 specific scales, 1 additional unspecific scale, and 3 general scores. The 9 dimensions are somatization, obsessive-compulsive symptoms, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, and psychoticism. The items are rated on a 5-point Likert scale (minimum 0: not at all; maximum 4 = very strong). The SCL-90-R was calculated according to the Global Severity Index (GSI) manual with the term: GSI = GS/(90 -number of missing items); GS = sum score of all answered items. The resulting scores are transformed to t-values, where t-values between 60 and 70 indicate a distinct burden of psychological distress and t-values of 70 and above indicate a high burden of psychological distress. The maximum score is 80 [30] . The GSI is a measure of psychological distress [30, 31] .
Pain intensity at commonly painful tender points was evaluated by the Tender Point Score [32] . It consists of a body diagram where patients can rate the pain intensity at 24 locations of the front and the back side of the body on a 6-point Likert scale ranging from 0 = 'no pain' to 5 = 'maximum pain'.
Self-administered outcome measures were applied at T0, T1, and T2, with the exception of the PGIC (only T1 and T2) and the SCL-90-R (only T0 and T2). The SCL-90-R was only used at T0 and T2 to reduce the burden for the patients.
Secondary outcome measures included the clinical test Tender Point Count [33] , which measures widespread pain and tenderness. According to the manual, the examiner applied discretely increasing pressure of up to 4 kg/cm 2 to each of the 18 tender points typical of FM. When the patients expressed pain, the tender point was considered as positive. Besides the number of tender points, we calculated the mean of the pain-pressure threshold of both sides of the trapezius muscle in order to compare the local change of tenderness between T0 and T1. To locate the tender point, the examiner palpated a line between the acromioclavicular joint and the spinous process of vertebra C7 and searched for the point with the highest tenderness. Then, the Fischer dolorimeter with a stamp of 1 cm 2 was used to apply vertical pressure to the selected point. The force was increased by 1 kg/s until the patient reported pain. Pressure was measured in kg/cm 2 [34, 35] . All clinical tests were assessed only at T0 and T1. The assessor was blinded to the treatment allocation.
After trial commencement, the trial outcomes were not changed.
Group Comparison
The null hypothesis (H0) for the primary outcome was that there is no difference in the changes of the FIQ total score between the treatment and the control group at T2 (change score: T2-T0). Analogously, the H0 for the secondary outcome measures was that there are no differences in the changes at T1 (T1-T0) and T2 (T2-T0). The change scores were tested for normal distribution by histograms, comparisons of means and medians, and by Shapiro-Wilk test. We adhered to the Shapiro-Wilk test for the final decision of the applied significance test. For normally distributed data, group differences were assessed by analysis of variance (ANOVA), with baseline scores as a covariate. Groupwise heteroscedasticity was assessed by Levene's test. For non-normally distributed data, the Mann-Whitney U test was performed. Due to the small sample size, no subgroup analyses were performed.
Additionally, effect sizes (ES) were calculated by Cohen's d at the end of treatment and at the 3-month follow-up. Cohen's d is the difference of 2 means divided by the pooled standard deviation [36] . Positive values indicate a beneficial effect for the intervention groups. All data analyses were performed by using SPSS for Windows, version 23. Outcome scores were illustrated by simple graphs.
Results
Patients
Between April 2005 and April 2006, 40 female patients were enrolled in the study. Recruitment was stopped after reaching the intended sample size. The patient flow is shown in figure 1 . In the intervention group as well as in the control group, 1 patient withdrew for private reasons before the end of treatment. Another 2 patients dropped out before follow-up (T2), 1 person in each group. Both patients did not return the set of questionnaires and could not be contacted despite several attempts. Finally, 36 out of 40 patients could be analyzed (90%).
Participant Characteristics and Baseline Scores
The participant characteristics showed no statistically significant differences between the treatment group and the control group (table 1). The baseline scores of the outcome measures are presented in table 2. In the FIQ total score and most other measures there were no statistically significant group differences. Only the Vitality scale (p = 0.05) and the Role-Emotional scale (p = 0.04) of the SF-36 showed a significantly better health status in the control group.
Primary and Secondary Outcome Measures
The results for the primary outcome FIQ and for all secondary outcome measures are shown in table 2. Figure 2 displays the change scores of the FIQ for the treatment and the control group at T1 and T2. The FIQ total scores improved in both the treatment and the control group between the beginning and the end of treatment, but there was no significant group difference (p = 0.95, ES = 0.02). Also at the follow-up there were no statistically significant group differences, even though the intervention group retained more from the initial improvement (p = 0.43, ES = 0.26). All but 1 secondary outcome measure showed no significant differences in the changes between the groups. Only the pain-pressure threshold at the end of the treatment was significantly higher in the intervention group (p = 0.016, ES = 0.84).
Side effects were reported neither in the treatment nor in the control group.
Discussion
In this RCT, EMG-BFB did not improve the health status of the patients with FM. The primary outcome measure (FIQ) and all secondary outcome measures, with the exception of the pressure-pain threshold in the trapezius muscle, showed no superiority of EMG-BFB in addition to usual care compared to usual care alone.
A meta-analysis and systematic review from 2013 included 4 RCTs that compared EMG-BFB to controls [15] . The results of our study are in line with this meta-analysis with respect to the lack of effects on quality of life, but they are in contrast to the positive effects on pain described in the meta-analysis. One reason for these positive effects in the meta-analysis may be the fact that the patients were taught additional relaxation techniques in 3 of the 4 RCTs. Since relaxation training alone has a beneficial effect in the treatment of chronic pain and is recommended for treatment of FM [37] [38] [39] [40] , it remains unclear if the positive effects on pain were due to EMG-BFB. Only in 1 study of the meta-analysis the patients learned to relax their muscles according to visual and audio feedback without additional relaxation strategies [41] . That study described a significant reduction of pain measured by a visual analog scale (VAS), but found no group difference for the FIQ.
In this study, the local pressure-pain threshold increased significantly in the area were the EMG-BFB (ES = 0.84) was applied, but this local effect did not result in reduced self-reported pain. Accordingly, the hypothesis that reduced local tenderness may result in general pain relief in patients with FM was not confirmed. However, the increase of the pressure-pain threshold supports the positive effectiveness of EMG-BFB for the treatment of local muscle pain. One limitation of this study is that patients were not blinded to the intervention. A sham BFB treatment was not feasible because patients would very likely recognize that they receive a sham intervention. However, since the intervention group received more attention but still showed no benefit, it is unlikely that the omission of patient blinding had changed the main results of the study.
In this study, we did not assess for compliance to the home exercise program of muscle relaxation training. Accordingly, it is possible that low compliance to the home exercises led to the lack of a significant treatment effect.
This study had a rather small sample size. A later study revealed that the minimal clinically important difference (MCID) of the FIQ is a 14% change in the total score [42] . The effect in our study with 6.0% improvement in the FIQ was clearly below the MCID. However, a post-hoc sample size calculation based on the MCID would result in a sample size of 178 patients to detect an MCID with α = 0.05, a power of 90%, and a drop-out rate of 10%.
In conclusion, this study suggests that EMG-BFB is not effective in older patients with FM who are quite chronic and have been referred to a tertiary hospital. According to a previous review, it is possible that EMG-BFB amplifies the benefits of specific relaxation strategies in a more comprehensive intervention [15] . However, further studies with larger sample sizes would be necessary to evaluate the effectiveness of EMG-BFB training in combination with relaxation training compared to relaxation training alone, to evaluate the effectiveness of EMG-BFB training as part of multicomponent treatment programs.
